Cargando…

High Treatment Success Rates When Switching to Once Daily Nevirapine Containing Antiretroviral Therapy

INTRODUCTION: Two recent studies have highlighted low rates of virological response to once daily nevirapine containing combination antiretroviral therapy (CART) in treatment naïve HIV-1 infected subjects. AIM: We assessed factors associated with treatment responses in a cohort of HIV-1 infected, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benzie, Andrew, Marett, Brett, Mackie, Nicola E, Winston, Alan
Formato:	Texto
Lenguaje:	English
Publicado:	Bentham Open 2008
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627512/ https://www.ncbi.nlm.nih.gov/pubmed/19274065 http://dx.doi.org/10.2174/1874613600802010089

Ejemplares similares

Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan
por: Lee, Chun-Yuan, et al.
Publicado: (2017)

Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
por: Yone, Eric W Pefura, et al.
Publicado: (2012)

Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy.
por: Kakande, Betty, et al.
Publicado: (2015)

2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir
por: Hsu, Ricky, et al.
Publicado: (2019)

Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: a case report
por: Gökengin, Deniz, et al.
Publicado: (2002)

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2015)

Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole
por: Manosuthi, Weerawat, et al.
Publicado: (2007)

Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort
por: Scarsi, Kimberly K., et al.
Publicado: (2016)

Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial
por: Winston, Alan, et al.
Publicado: (2014)

The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)-containing once-daily highly active antiretroviral therapy (HAART)
por: Cassetti, I, et al.
Publicado: (2010)

Adverse Events in a Cohort of HIV Infected Pregnant and Non-Pregnant Women Treated with Nevirapine versus Non-Nevirapine Antiretroviral Medication
por: Aaron, Erika, et al.
Publicado: (2010)

Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?
por: Nachega, Jean B, et al.
Publicado: (2011)

Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death
por: Heck, Carley J. S., et al.
Publicado: (2020)

557. Evaluation of Clinical Response of a Two Tablet Once Daily Antiretroviral Regimen in Antiretroviral Experienced HIV-Infected Patients
por: Maki, Gina, et al.
Publicado: (2018)

Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-Trial)
por: Weberschock, T, et al.
Publicado: (2009)

Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study
por: Mwesigire, Doris Mutabazi, et al.
Publicado: (2015)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patients
por: Umapathy, Shankarkumar, et al.
Publicado: (2011)

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
por: Juday, Timothy, et al.
Publicado: (2013)

Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?
por: Kumarasamy, N., et al.
Publicado: (2011)

Efficacy and Patient Satisfaction of Dipeptidyl Peptidase-4 Inhibitor After Switching From Once-Daily DPP-4 Inhibitor to Once-Weekly Regimen
por: Suzuki, Katsunori, et al.
Publicado: (2018)

Efficacy and safety of a switch from twice-daily tacrolimus to once-daily generic tacrolimus in stable liver transplant patients
por: Kim, Jong Man, et al.
Publicado: (2021)

The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study
por: Rokx, Casper, et al.
Publicado: (2014)

Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens
por: Bommenel, T, et al.
Publicado: (2010)

Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults
por: Fehintola, Fatai A., et al.
Publicado: (2012)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
por: Wysham, C, et al.
Publicado: (2011)

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
por: Woodcock, Ashley, et al.
Publicado: (2011)

Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study
por: Sinha, Sanjeev, et al.
Publicado: (2013)

Incidence and Determinants of Nevirapine and Efavirenz-Related Skin Rashes in West Africans: Nevirapine's Epitaph?
por: Sarfo, Fred Stephen, et al.
Publicado: (2014)

Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese HIV/AIDS Patients: Multicentric Observation Cohort
por: Li, Taisheng, et al.
Publicado: (2008)

The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment
por: Skinner-Adams, Tina S., et al.
Publicado: (2012)

Factors affecting high-density lipoprotein cholesterol in HIV-infected patients on nevirapine-based antiretroviral therapy
por: Padmapriyadarsini, C., et al.
Publicado: (2017)

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
por: Toyos, Melissa M.
Publicado: (2019)

Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, HIV-Infected Patients
por: Julio, Montaner SG, et al.
Publicado: (2006)

Tacrolimus Exposure Before and After a Switch From Twice-Daily Immediate-Release to Once-Daily Prolonged Release Tacrolimus: The ENVARSWITCH Study
por: Monchaud, Caroline, et al.
Publicado: (2023)

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
por: Bajaj, Harpreet S., et al.
Publicado: (2021)

Solid-State Characterization of Nevirapine
por: Sarkar, Mahua, et al.
Publicado: (2008)

A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy
por: Washington, Samuel L, et al.
Publicado: (2010)

Frequency of Antiretroviral Resistance Mutations among Infants Exposed to Single-Dose Nevirapine and Short Course Maternal Antiretroviral Regimens: ACTG A5207
por: Hitti, Jane, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_eflj4kfa0t2kgiiqh32h3fl3f4